filings.toolsItem 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
5K characters. Original on sec.gov ·
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Common stock
Our common stock trades on the Nasdaq Global Select Market under the symbol AMGN. As of February 10, 2026, there were approximately 3,824 holders of record of our common stock.
Performance graph
The following graph shows the value of an investment of $100 on December 31, 2020, in each of Amgen common stock, the Amex Biotech Index, the Amex Pharmaceutical Index and Standard & Poor’s 500 Index. All values assume reinvestment of the pretax value of dividends and are calculated as of December 31 of each year. The historical stock price performance of the Company’s common stock shown in the performance graph is not necessarily indicative of future stock price performance.
| 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | ||||||||||||||||||||||||||||||
| Amgen (AMGN) | $100.00 | $100.87 | $121.54 | $137.97 | $128.71 | $166.88 | |||||||||||||||||||||||||||||
| Amex Biotech (BTK) | $100.00 | $96.48 | $92.61 | $95.27 | $101.21 | $126.28 | |||||||||||||||||||||||||||||
| Amex Pharmaceutical (DRG) | $100.00 | $123.37 | $132.94 | $143.21 | $150.48 | $186.40 | |||||||||||||||||||||||||||||
| Standard & Poor’s 500 (SPX) | $100.00 | $128.68 | $105.29 | $133.03 | $165.98 | $195.62 |
The material in the above performance graph is not soliciting material, is not deemed filed with the SEC and is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made on, before or after the date of this filing and irrespective of any general incorporation language in such filing.
Stock repurchase program
During the year ended December 31, 2025, we had one outstanding stock repurchase program, under which repurchase activity was as follows:
| Total number of shares purchased | Average price paid per share | Total number of shares purchased as part of publicly announced program | Maximum dollar value that may yet be purchased under the program | |||||||||||||||||||||||
| October 1–October 31 | — | $ | — | — | $ | 6,779,253,902 | ||||||||||||||||||||
| November 1–November 30 | — | $ | — | — | $ | 6,779,253,902 | ||||||||||||||||||||
| December 1–December 31 | — | $ | — | — | $ | 6,779,253,902 | ||||||||||||||||||||
| — | — | |||||||||||||||||||||||||
| January 1–December 31(1) | — | $ | — | — |
(1) During the year ended December 31, 2025, the Company purchased 1,700 shares at an average price paid of $284.67 per share from staff members to satisfy federal law compliance obligations. These shares were not repurchased under our stock repurchase program.
Dividends
For the years ended December 31, 2025 and 2024, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to approval by our Board of Directors. Additional information required by this item is incorporated herein by reference to Part IV—Note 17, Stockholders’ equity, to the Consolidated Financial Statements.
Securities Authorized for Issuance Under Existing Equity Compensation Plans
Information about securities authorized for issuance under existing equity compensation plans is incorporated by reference from Part III, Item 12—Securities Authorized for Issuance Under Existing Equity Compensation Plans.
Previous: Item 4. MINE SAFETY DISCLOSURES · Next: Item 6. RESERVED